R&D News | pharmaphorum

News

Madrigal builds in MASH with $4.4bn+ Ribo alliance

Already sitting on a blockbuster therapy for MASH, Madrigal has beefed up its pipeline with six siRNA candidates licensed from China's Ribo.

News

UK moves ahead with GP patient data sharing plan

The UK government has asked the NHS to start putting together the platforms to allow anonymised primary care patient data to be used by researchers.

News

Kailera, Hengrui stake claim to oral weight loss category

Chasing Novo Nordisk and Eli Lilly, Kailera and Hengrui have reported 12.1% weight loss in phase 2 with their oral GIP/GLP-1 agonist ribupatide.

News

Takeda signs $1.7bn AI alliance with Iambic

Iambic bags another pharma partner, Takeda, which plans to use its AI platform to find drugs for cancer, gastrointestinal, and inflammatory disorders.

News

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

In its second major deal in two days, Eli Lilly has reached an agreement to buy in vivo CAR-T developer Orna Therapeutics for up to $2.4bn.

News

Data builds on Roche's dominance in primary progressive MS

Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.

Madrigal builds in MASH with $4.4bn+ Ribo alliance

UK moves ahead with GP patient data sharing plan

Kailera, Hengrui stake claim to oral weight loss category

Takeda signs $1.7bn AI alliance with Iambic

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

Data builds on Roche's dominance in primary progressive MS

ESMO26: Sac-TMT delivers the goods in PD-L1-negative NSCLC

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks